Arcus Biosciences, Inc. (RCUS) Form 8-K — Oct 21, 2026
Arcus Biosciences filed an 8-K estimating approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026. The figure is a preliminary, unaudited estimate and has not been reviewed by its auditor, Ernst & Young LLP. The disclosure, furnished under Item 2.02, contains no revenue, earnings, or guidance figures — it is limited to a preliminary liquidity snapshot ahead of full financials.
Key figures
- Cash Position
- 694000000
- Cash as of
- September 30, 2026
- Preliminary estimate
- Yes
- Auditor review status
- Not audited or reviewed by Ernst & Young LLP
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.